(ARJO-B) Arjo (publ) - Ratings and Ratios

Arjo AB (publ) is a global medical device company specializing in solutions that enhance clinical and financial outcomes for healthcare providers. Headquartered in Malmö, Sweden, the company has been operational since 1957 and serves institutions across Europe, Asia-Pacific, South America, Africa, and international markets. Its product portfolio includes advanced systems for patient handling, hygiene, and disinfection, as well as medical beds designed to prevent pressure injuries. Arjo also offers diagnostics and treatment solutions for conditions such as deep vein thrombosis, edema, and leg ulcers, complemented by specialized care solutions for dementia, bariatric needs, and rehabilitation. The company provides architects and planners with tailored solutions for healthcare facilities and offers maintenance, rental, and financing options to optimize equipment accessibility. Arjo serves both acute and long-term care institutions, addressing the full continuum of patient care needs.

Arjo AB (publ) is traded on the Stockholm Stock Exchange under the ticker ARJO-B. The company operates within the Health Care Distributors sub-industry and maintains a strong market presence with a market capitalization of 8,835.68M SEK. Its current stock price is 32.44 SEK, with a price-to-earnings ratio of 17.73 and a forward P/E of 12.99, indicating expectations of future earnings growth. The price-to-book ratio stands at 1.05, while the price-to-sales ratio is 0.78, suggesting moderate valuation levels. The return on equity is 5.98%, reflecting the companys profitability. Arjos average trading volume over the past 20 days is 542,622 shares, with a last price of 32.44 SEK. The stocks short-term momentum is signaled by its SMA 20 at 34.29, SMA 50 at 37.03, and SMA 200 at 38.34, while the ATR of 1.05 indicates relatively low volatility.

3-Month Forecast: Based on the provided and , Arjo AB (publ) is expected to experience a mixed outlook. The stock price is currently below its SMA 20, SMA 50, and SMA 200, suggesting short-term bearish momentum. However, the forward P/E of 12.99 indicates potential undervaluation, which could attract investors seeking long-term growth. The low ATR of 1.05 signals stable price movements, reducing near-term volatility risks. With a P/S ratio of 0.78, the companys valuation is relatively attractive compared to its peers. Over the next three months, the stock may consolidate near current levels, with potential upside driven by improving fundamentals or market sentiment shifts. Investors should monitor earnings reports and industry trends for clearer directional signals.